Bayer’s Monsanto debacle sows bitter M&A lessons
A ​decade on, the German ⁠pharma giant is ​worth less than ​the $62 bln it paid for Roundup's maker. ​Known legal risks ...
Bayer says no plans to restructure despite litigation threat
By Renee Hickman and Tom Polansek CHICAGO, June 2 (Reuters) - Bayer has no plans to spin off Monsanto, a representative said on Tuesday, even as the company faces an avalanche of lawsuits over its ...
Bayer Shares Fall on Renewed Uncertainty Over $7 Billion U.S. Settlement
Bayer shares fell after plaintiffs sought to transfer a proposed $7.25 billion U.S. settlement over Roundup weedkiller to a ...
Bayer shares slide as Roundup settlement faces new legal challenge
Bayer shares drop as Roundup settlement faces federal court shift, raising litigation risk and timeline doubts.
Bayer Wins $2B BASF Arbitration Appeal
Gleiss Lutz represented Bayer in the post-M&A arbitration. Sullivan & Cromwell and Jones Day represented Bayer in the initial ...
'There Are So Many Objections': 100+ Objectors Flag Faults in $7.25B Roundup Settlement
More than 100 class members and a dozen health care companies objected to the Roundup settlement, which is up for final ...